drugset
drugset / Trial / NCT05238792

Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors

NCT05238792 ↗

Phase 1 Recruiting 36 enrolled Children's National Research Institute
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy for patients with high-risk solid tumors due to the presence of refractory, relapsed and/or minimal residual detectable disease following conventional therapy. Conventional therapy may include chemotherapy, surgery, radiation, autologous stem cell transplant, or targeted therapy.

Timeline

Start
2021-11-17
Primary completion
2028-10
Completion
2029-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tumor-associated antigen-specific T cell Unknown 2e+07 cells —
Subject Tumor-associated antigen-specific T cell Unknown 4e+07 cells —
Subject Tumor-associated antigen-specific T cell Unknown 8e+07 cells —

Indications

cancer